Skip to content

SkIn, Muscle and Bone Aging Determinants in HIV Infected-patients.

Determinants of Skin, Muscle and Bone Aging in HIV-1 Infected Patients

Status
Terminated
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04067219
Acronym
SIMBAD
Enrollment
123
Registered
2019-08-26
Start date
2012-05-03
Completion date
2013-12-19
Last updated
2026-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV-1-infection, Marker; Structural

Keywords

Alterations

Brief summary

this study consists of the study of markers of skin, muscular, neurocognitive and bone aging in HIV infected adults and to compare the frequency of these signs to the general population of same gender and age.

Detailed description

Nowadays, the elevated frequency of cancers as well as cardiovascular, neurocognitive and bone diseases seems to denote a process of accelerated aging in the treated HIV-infected population of western countries, who are 40 to 50 years old in median. Markers of age-related alterations should be compared to the distribution among the general population whenever possible, to disentangle the effect of HIV and "normal" ageing or ageing due to other conditions. Common mechanisms should be better understood, more specifically those related to the impact of tobacco, antiretroviral treatments, and nutritional components. For markers of skin, muscle, neurocognitive function and bone ageing, the distribution of the general population is available and, in addition, alteration of these markers might have common mechanisms, such as insufficiency in 25 hydroxy vitamin D or nutritional parameters. Therefore, a joint study of these three organs seems particularly relevant. This aim is to study markers of skin, muscular, neurocognitive and bone aging in HIV infected adults and to compare the frequency of these signs to the general population of same gender and age.

Interventions

PROCEDUREDXA (dual-energy x-ray absorptiometric) measurement

DXA, evaluation of muscular function and muscle strength; neurocognitive tests; non invasive analysis of mechanical skin properties; food frequency questionnaire; laboratory assessment (25 hydroxy vitamin D, calcium/phosphate metabolism, bone remodelling markers, T cell activation).

Sponsors

University Hospital, Bordeaux
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* HIV-1 infected patients included in the TISSOS-VIH substudy of the ARNS CO3 Aquitaine Cohort or who had a DXA measurement of the lumbar spine, femoral neck, and total body between 2004 and 2011 at the University Hospital of Bordeaux, * \> 18 years * Affiliated to the medical insurance * Having had at least one DXA measurement prior to the SIMBAD study visit * Written informed consent for the SIMBAD study

Exclusion criteria

* Hepatitis C virus co-infection * Pregnancy

Design outcomes

Primary

MeasureTime frameDescription
Proportion of patients with an alteration in bone, muscle, neurocognitive or skin parametersAt the earliest at the inclusion visit and within a 9-month window after inclusionpresence of osteoporosis or osteopenia on DXA (T-score \< -2.5 and \<-1, respectively), locomotor test results \> 2 standard deviations of the mean of the general population, presence of premature hair whitening in patients aged \< 40 years (defined by\>50% of gray hair before the age of 40)

Contacts

PRINCIPAL_INVESTIGATORPatrick MERCIE, Pr

University Hospital, Bordeaux

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 25, 2026